Janney Montgomery Scott LLC Sells 1,590 Shares of Masimo Corporation (NASDAQ:MASI)

Janney Montgomery Scott LLC trimmed its position in Masimo Corporation (NASDAQ:MASI - Free Report) by 47.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,762 shares of the medical equipment provider's stock after selling 1,590 shares during the period. Janney Montgomery Scott LLC's holdings in Masimo were worth $294,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Jones Financial Companies Lllp bought a new position in Masimo during the 4th quarter worth $27,000. Farther Finance Advisors LLC raised its position in shares of Masimo by 128.9% in the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 116 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of Masimo in the 4th quarter worth about $46,000. 85.96% of the stock is currently owned by institutional investors.

Insider Transactions at Masimo

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the transaction, the chief operating officer owned 24,172 shares of the company's stock, valued at $3,946,804.16. This trade represents a 29.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.70% of the company's stock.

Masimo Stock Down 2.1%

MASI stock traded down $3.67 during mid-day trading on Friday, reaching $167.67. 498,674 shares of the company traded hands, compared to its average volume of 639,289. The stock has a market cap of $9.09 billion, a price-to-earnings ratio of -18.28 and a beta of 1.19. The company has a quick ratio of 1.62, a current ratio of 2.17 and a debt-to-equity ratio of 0.67. Masimo Corporation has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The firm's 50 day moving average price is $161.89 and its 200 day moving average price is $166.46.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. The business had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The company's quarterly revenue was down 24.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 EPS. As a group, equities research analysts predict that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. BTIG Research set a $193.00 target price on Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Wells Fargo & Company reduced their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen downgraded Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Raymond James Financial reduced their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $191.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.